IVERMECTIN TABLETS
(IVERMECTINI COMPRESSI)

DRAFT MONOGRAPH FOR INCLUSION IN
The International Pharmacopoeia
(May 2018)

DRAFT FOR COMMENTS

Should you have any comments on this draft, please send these to Dr Herbert Schmidt,
Medicines Quality Assurance Programme, Technologies, Standards and Norms, Department of
Essential Medicines and Health Products, World Health Organization, 1211 Geneva 27,
Switzerland; fax: (+41 22) 791 4730 or email: schmidt@who.int by 31 July 2018.

In order to speed up the process for receiving draft monographs and for sending
comments, please let us have your email address (to bonnyw@who.int) and we will add it
to our electronic mailing list. Please specify if you wish to receive monographs.
**SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/16.692:**

Ivermectin tablets

*(Ivermectini compressi)*

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monograph drafted</td>
<td>December 2016</td>
</tr>
<tr>
<td>Discussion at consultation on specifications for medicines</td>
<td>2–4 May 2018</td>
</tr>
<tr>
<td>Laboratory investigations to develop, optimize, verify or validate</td>
<td>May 2017–March 2018</td>
</tr>
<tr>
<td>the proposed analytical tests and specifications</td>
<td></td>
</tr>
<tr>
<td>Draft revision sent out for public consultation</td>
<td>June–August 2018</td>
</tr>
<tr>
<td>Presentation to WHO Expert Committee on Specifications for</td>
<td>October 2018</td>
</tr>
<tr>
<td>Pharmaceutical Preparations for possible adoption</td>
<td></td>
</tr>
<tr>
<td>Further follow-up action as required</td>
<td></td>
</tr>
</tbody>
</table>
IVERMECTIN TABLETS
(IVERMECTINI COMPRESSI)

[Note from the Secretariat. The draft monograph is proposed for inclusion in The
International Pharmacopoeia. It was elaborated based on laboratory investigations
performed by a collaborating laboratory and on information provided by the
manufacturer and found in other pharmacopoeias.]

Category. Antifilarial.

Storage. Ivermectin tablets should be kept in well-closed containers, protected from
light, and stored at a temperature below 30°.

Additional information. Strength in the current WHO Model List of Essential
Medicines (EML): 3 mg per tablet. Strength in the current WHO EML for children: 3
mg per tablet. Additional strengths available: 6 mg per tablet. This monograph is
applicable for tablets containing 3 mg and 6 mg Ivermectin per tablet.

Requirements
Complies with the monograph on Tablets.

Definition. Ivermectin tablets contain not less than 90.0% and not more than 110.0%
of the amount of Ivermectin stated on the label, calculated as the sum of the
Ivermectin components $\text{H}_2\text{B}_1\text{a} (\text{C}_{48}\text{H}_{74}\text{O}_{14})$ and $\text{H}_2\text{B}_1\text{b} (\text{C}_{47}\text{H}_{72}\text{O}_{14})$.

Identity tests
- Either test A or test B may be applied.

A. Carry out the test as described under "1.14.4 High-performance liquid
chromatography using the conditions given under “Assay”, method A. The retention time of the principal peaks in the chromatogram obtained with solution (1) corresponds to the retention times of the peaks due to ivermectin in the chromatogram obtained with solution (2).

B. Carry out the test as described under 1.14.1 Thin-layer chromatography using silica gel R4 or R2 as the coating substance and a mixture of 90 volumes of dichloromethane R, 8 volumes of methanol R and 0.8 volume of ammonia (≈260 g/L) TS as the mobile phase. Apply separately to the plate 30 µL of each of the following 2 solutions in methanol R. For solution (A) transfer a quantity of the powdered tablets, used to prepare solution (1) as described under “Assay”, method A, containing the equivalent of 25 mg of ivermectin into a 25 mL volumetric flask, add 2.5 mL of water R and sonicate for 10 minutes. Add about 15 mL of methanol R, mix, and sonicate for 5 minutes. Allow the solution to cool to room temperature. Dilute with methanol R to volume, mix and filter. For solution (2) dissolve 25 mg of ivermectin RS in methanol R and dilute to 25.0 mL with the same solvent.

Develop the plate. After removing the plate from the chromatographic chamber allow it to dry in air or in a current of air. Examine the chromatogram under ultraviolet light (254 nm).

The partly separated spots in the chromatogram obtained with solution (A) correspond in position, appearance, and intensity with the two partly separated principal spots due to ivermectin in the chromatogram obtained with solution (B).

Dissolution. Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms using as the dissolution medium 900 mL of a solution of 0.5% sodium
dodecyl sulfate R in phosphate buffer, pH 7.0 (0.01 mol/L) TS and rotating the paddle at 50 revolutions per minute. At 45 minutes withdraw a sample of 10 mL of the medium through an in-line filter and use the filtrate as solution (1). For solution (2) dissolve 33.0 mg of ivermectin RS in dissolution medium and dilute to 250.0 mL with the same solvent. For 3 mg tablets dilute 5.0 mL of solution (2) to 200.0 mL with dissolution medium. Use this solution as solution (3). For 6 mg tablets dilute 5.0 mL of solution (2) to 100.0 mL with dissolution medium. Use this solution as solution (3).

Carry out the test as described under 1.14.4 High-performance liquid chromatography using the chromatographic conditions as described under “Assay”, method A but injecting alternately 100 µL each of solution (1) and (3).

For each of the tablets calculate the total amount of ivermectin (component H$_2$B$_{1a}$ and component H$_2$B$_{1b}$) in the medium considering the assigned contents of component H$_2$B$_{1a}$ and component H$_2$B$_{1b}$ in ivermectin RS. Evaluate the results as described under 5.5 Dissolution test for solid oral dosage forms, Acceptance criteria. The amount of ivermectin (component H$_2$B$_{1a}$ and component H$_2$B$_{1b}$) in solution for each tablet is not less than 80% (Q) of the amount declared on the label.

Related substances. Carry out the test as described under 1.14.4 High-performance liquid chromatography using a stainless steel column (25 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (5 µm).\(^1\)

As the mobile phase use a mixture of 39 volumes of water R, 55 volumes of methanol R and 106 volumes of acetonitrile R. Operate with a flow rate of 1.5 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 245 nm and, for impurity D, at 280 nm.

\(^1\) A Restek or Agilent PoroShell column or a Zorbax SB C18 column were found suitable.
Prepare the following solutions. For solution (1) use the powdered tablets described under “Assay”, method A. Transfer a quantity containing the equivalent of 25.0 mg of Ivermectin into a 100 mL volumetric flask, add 10 mL of water R and sonicate for 10 minutes. Add about 60 mL of methanol R, mix and sonicate for 5 minutes. Allow the solution to cool to room temperature. Dilute with methanol R to volume, mix and filter. For solution (2) dilute 1.0 mL of solution (1) to 100.0 mL with methanol R. For solution (3) dissolve 25.0 mg of ivermectin RS and dilute to 50.0 mL with methanol. For solution (4) dilute 1.0 mL of solution (3) to 100.0 mL with methanol. Dilute 5.0 mL of this solution to 100.0 mL. For solution (5) use a solution containing 5.0 µg of 3-tert-Butyl-4-hydroxyanisole R per mL methanol R. For solution (6) weigh about 2.2 mg of the copper (I) bromide R into a 10 mL volumetric flask. Add 5.0 mL of solution (1) and 100 µL of tert-butyl hydroperoxide R and dilute to volume. Mix well and let the solution stand at room temperature for approximately 20 minutes. Use solution (6) within 2 hours after preparation.

Inject 20 µL each of solution (3) and (4). The test is not valid unless in the chromatogram obtained with solution (3) the resolution between the peaks due to ivermectin component H₂B₁b (with a relative retention of about 0.74 with reference to the component H₂B₁a) and due to component H₂B₁a (with a retention time of about 34 minutes) is at least 3.0 and the symmetry factor of the peak due to component H₂B₁b is not greater than 2.5. In the chromatogram obtained with solution (4) the signal-to-noise ratio of the principal peak is at least 10.

Inject alternately 20 µL each of solutions (1), (2), (5) and (6). Record the chromatograms for about 2 times the retention time of the principal peak.

Use the chromatogram obtained with solution (6) to identify the peak due to impurity D. In the chromatogram obtained with solution (1) the following impurity, if present,
is eluted at the following relative retention with reference to component $H_2B_{1a}$ (with a retention time of about 34 minutes): impurity D about 0.69.

In the chromatogram obtained with solution (1):

- the area of any peak corresponding to impurity D is not greater than the area of the principal peak in the chromatogram obtained with solution (5) (2.0%);
- the area of any impurity peak with a relative retention of 1.3 to 1.5 with reference to the principal peak is not greater than 2.7 times the area of the principal peak in the chromatogram obtained with solution (2) (2.7%);
- the area of any other impurity peak is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (1%);
- determine the sum of the areas of all impurities, other than impurity D, using solution (2) as a reference solution. Disregard any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with solution (2) (0.1%). Calculate the sum of all impurities considering the concentration found for impurity D. The sum of all impurities is not greater than 6%.

**Assay**

- For 3 mg tablets either method A or B may be applied.
- For 6 mg tablets calculate the percentage content of ivermectin in the tablets using the of the declared quantity of ivermectin in the tablets. For tablets where the declared quantity of ivermectin is 5% or less of the total weight of the formulation either method A or B may be applied. For tablets where the declared quantity of ivermectin is more than 5% apply method A.

**A.** Carry out the test as described under 1.14.4 High-performance liquid chromatography, using a stainless steel column (25 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with
chemically-bonded octadecylsilyl groups (5 µm).²

As the mobile phase use a mixture of 13 volumes of water R, 35 volumes of methanol R and 53 volumes of acetonitrile R. Operate with a flow rate of 1.5 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 245 nm.

Prepare the following solutions. For solution (1) weigh and powder 20 tablets. Transfer a quantity of the powdered tablets, containing the equivalent of 25.0 mg of ivermectin into a 100.0 mL volumetric flask, add 10 mL of water R and sonicate for 10 minutes. Add about 60 mL of methanol R, mix, and sonicate for 5 minutes. Allow the solution to cool to room temperature. Dilute with methanol R to volume, mix and filter. For solution (2) dissolve 25.0 mg of ivermectin RS in methanol R and dilute to 100.0 mL with the same solvent.

Inject alternately 10 µL each of solution (1) and (2). Record the chromatograms for about 2 times the retention time of the principal peak.

The test is not valid unless in the chromatogram obtained with solution (2) the resolution between the peaks due to component H₂B₁b (with a relative retention of about 0.74 with reference to component H₂B₁a) and due to component H₂B₁a (retention time about 34 minutes) is at least 3.0 and the symmetry factor of the peak due to component H₂B₁b is not greater than 2.5.

Measure the areas of the peaks corresponding to the components H₂B₁a and H₂B₁b obtained in the chromatograms of solution (1) and (2) and calculate the percentage content of ivermectin (component H₂B₁a and component H₂B₁b) in the tablets considering the assigned contents of component H₂B₁a and

² A Restek or Agilent PoroShell column or a Zorbax SB C18 column were found suitable.
component H₂B₁b in ivermectin RS.

B. Use the average of the 10 individual results obtained in the test for “Uniformity of content”.

**Uniformity of content**

3 mg tablets comply with the test for 5.1 *Uniformity of content for single-dose preparations* using the following method of analysis. 6 mg tablets comply with the test in case the declared quantity of ivermectin is 5% or less of the total weight of the formulation.

Carry out the test as described under 1.14.4 *High-performance liquid chromatography* using the chromatographic conditions as described under “Assay”, method A.

Prepare the following solutions using mobile phase as diluent. For solution (1) transfer one tablet to a 25 mL volumetric flask, add 5 mL of water R and sonicate for 10 minutes. Add about 15 mL of methanol R, mix and sonicate for 5 minutes. Allow the solution to cool to room temperature. Dilute with methanol R to volume, mix and filter. For 6 mg tablets dilute 5.0 mL of this solution to 10.0 mL with methanol R. For solution (2) dissolve 30.0 mg of ivermectin RS in methanol R and dilute to 250.0 mL with the same solvent.

Inject alternately 25 µL each of solution (1) and (2). Measure the areas of the peaks corresponding to the components H₂B₁a and H₂B₁b obtained in the chromatograms of solution (1) and (2) and calculate the percentage content of ivermectin (component H₂B₁a and component H₂B₁b) in each tablet using the declared contents of component H₂B₁a and component H₂B₁b in ivermectin RS.

**Impurities**
The impurities limited by the requirements of this monograph include those listed in the monograph for Ivermectin.

New reagents

Phosphate buffer, pH 7.0 (0.01 mol/L) TS

Procedure. Dissolve 0.136 g of potassium dihydrogen phosphate R in sufficient water to produce 100 mL. Separately dissolve 2.681 g of disodium hydrogen phosphate R in sufficient water to produce 100 mL. Mix 38.9 mL of the potassium phosphate solution with 61.1 mL of the sodium phosphate solution.

3-tert-Butyl-4-hydroxyanisole R

C_{11}H_{16}O_{2}; 180.24; [25013-16-5]

Description. White to light yellow powder.

Use a suitable grade.

Copper (I) bromide R

CuBr; 143.45; [7787-70-4]

Description. Pale green powder.

Use a suitable grade.

Reference substance to be established:

Ivermectin RS

***